Skip to main content
. Author manuscript; available in PMC: 2019 Sep 19.
Published in final edited form as: Antivir Ther. 2011 Nov 3;17(2):327–336. doi: 10.3851/IMP1946

Figure 2:

Figure 2:

Figure 2:

Figure 2:

Proportion of genomes showing the specified NVP and lamivudine resistance mutations detected by SGS in samples obtained 6 weeks after sdNVP in women receiving sdNVP alone (panel A), sdNVP plus CBV for 4 days (panel B) or for 7 days (panel C). Vertical bars show data from individual women. None indicates genomes with no resistance mutations.